Citius Pharmaceuticals Inc (CTXR)
1.003
0.00 (0.00%)
USD |
NASDAQ |
Mar 22, 16:00
1.003
0.00 (0.00%)
After-Hours: 17:40
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 146.70M |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -43.82% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | -- |
| Price to Book Value | 1.427 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | -- |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 98.88% |
News
Headline
Wire
Time (ET)
PR Newswire
02/10 16:30
Yahoo
01/16 07:09
PR Newswire
01/11 08:30
Yahoo
12/28 09:35
SA Breaking News
12/23 10:00
Events
| DATE | TIME | TYPE | PERIOD | REPORTED EPS |
ESTIMATED EPS |
SURPRISE | |
| 05/12/2023* | -- | Results | Q2 2023 | -- | -0.05 | -- | |
| 02/10/2023 | -- | Results | Q1 2023 | -- | -- | -- | |
| 08/11/2022 | -- | Results | Q3 2022 | -0.06 | -0.06 | 0.00% | |
| 05/12/2022 | -- | Results | Q2 2022 | -0.05 | -0.07 | 28.57% | |
| 02/10/2022 | -- | Results | Q1 2022 | -0.06 | -0.06 | 0.00% | |
| 08/12/2021 | -- | Results | Q3 2021 | -0.05 | -0.04 | -25.00% | |
| 05/13/2021 | -- | Results | Q2 2021 | -0.04 | -0.09 | 55.56% | |
| 02/11/2021 | -- | Results | Q1 2021 | -- | -- | -- |
*Estimated Date/Time
Earnings
Profile
Edit
| Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. |
| URL | http://www.citiuspharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 12, 2023 (est.) |
| Last Earnings Release | Feb. 10, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Dividends
| Dividend Per Share (TTM) | -- |
|
2017
2018
2019
2020
2021
6.00%
4.00%
2.00%
|
|
| Yield to Market | 0.00 |
| Yield to Sector | 0.00 |
| Yield to Industry | 0.00 |
| Last Dividend Amt. | -- |
| Dividend Frequency | -- |
| Last Ex-Dividend Date | -- |
| Yield (TTM) | 0% |
| Forward Yield | -- |
| Payout Ratio | -- |
| Cash Payout Ratio | -- |
| Consistent Payer (5Y) | No |
| Consistent Growth (5Y) | No |
Risk
Total Returns Comparison
Annual Total Returns Versus Peers
As of March 21, 2023.
Fundamentals
2017
2018
2019
2020
2021
4.00
2.00
1.00
| Revenue (TTM) | -- |
| Total Expenses (TTM) | 33.32M |
| Net Income (TTM) | -33.64M |
| Total Assets (Quarterly) | 114.00M |
| Total Liabilities (Quarterly) | 10.57M |
| Shareholders Equity (Quarterly) | 102.83M |
Ratings
Profile
Edit
| Citius Pharmaceuticals Inc is a biopharmaceutical company with a focus on anti-infectives in adjunct cancer care, unique prescription products, and stem cell therapy. It is currently advancing four proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; Halo-Lido, a topical formulation that is intended to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory distress syndrome. |
| URL | http://www.citiuspharma.com |
| Investor Relations URL | N/A |
| HQ State/Province | New Jersey |
| Sector | Healthcare |
| Industry | Biotechnology |
| Equity Style | Small Cap/Blend |
| Next Earnings Release | May. 12, 2023 (est.) |
| Last Earnings Release | Feb. 10, 2023 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ownership
| Insider Ownership Percentage | Upgrade |
Jul '20
Nov '20
Mar '21
80.00%
40.00%
10.00%
Analyst Coverage
|
Consensus Rating
|
|
|
Analyst Recommendation
|
|
Source: S&P Global
Other Resources
| Whale Wisdom | 13F Filings |
| Seeking Alpha | Call Transcripts |
| Nasdaq | Insider Trading |
| Nasdaq | Institutional Ownership |
| Nasdaq | Option Chain |
| SEC | SEC Filings |
| CTXR Tweets |